{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:24:29Z","timestamp":1769077469137,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Published data describing the efficacy and safety of autologous stem-cell transplantation (autoSCT) in post-transplant lymphoproliferative disorders (PTLD) is limited to case reports. This is a retrospective analysis of 21 patients reported to the EBMT registry who received an autoSCT for PTLD post solid organ transplant (SOT). Median age at autoSCT was 47 (range: 22\u201371) years. The commonest SOTs were kidney (48%) and liver (24%). Commonest histologies included DLBCL-type PTLD (14\/21) and plasmacytoma-like PTLD (3\/21). Patients received a median of two lines of therapy (range: 1\u20134) pre-autoSCT. ECOG performance status pre-autoSCT was 0 in 14% and 1 in 86%. Remission status pre-autoSCT was CR 47% and PR 38%. BEAM conditioning was used in 57% and high-dose melphalan in 10%. The median follow-up post-autoSCT was 64 months for alive patients. 3-year PFS was 62% [95% confidence interval (CI) 44\u201387%] and 3-year OS was 61% [95% CI:43\u201386]. There were 12 deaths, including four related to autoSCT. 100-day non-relapse-mortality (NRM) was 14% and 1-year NRM was 24%. This study suggests that autoSCT, although feasible and with potential therapeutic activity, is associated with a high NRM, primarily driven by infectious toxicity. A multi-disciplinary approach, expert microbiological input and stringent patient selection are required to optimise outcomes.<\/jats:p>","DOI":"10.1038\/s41409-021-01270-5","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T11:44:28Z","timestamp":1618573468000},"page":"2118-2124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Caillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Finel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf Ulrich","family":"Trappe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"De Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angus","family":"Broom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Bargetzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Koz\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2038-9730","authenticated-orcid":false,"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Kerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bjh.15263","volume":"182","author":"CB DeStefano","year":"2018","unstructured":"DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018;182:330\u201343.","journal-title":"Br J Haematol"},{"key":"1270_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"2","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;2:196\u2013206.","journal-title":"Lancet Oncol"},{"key":"1270_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","volume":"5","author":"RU Trappe","year":"2017","unstructured":"Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial. J Clin Oncol. 2017;5:536\u201343.","journal-title":"J Clin Oncol"},{"key":"1270_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"1270_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","volume":"5","author":"GW Van Imhoff","year":"2017","unstructured":"Van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J Clin Oncol. 2017;5:544\u201351.","journal-title":"J Clin Oncol"},{"key":"1270_CR6","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"1270_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ajh.20334","volume":"3","author":"RS Komrokji","year":"2005","unstructured":"Komrokji RS, Oliva JL, Zand M, Felgar R, Abboud CN. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol. 2005;3:211\u20135.","journal-title":"Am J Hematol"},{"key":"1270_CR8","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1080\/1042819021000040170","volume":"12","author":"NAM Bobey","year":"2002","unstructured":"Bobey NAM, Stewart DA, Woodman RC. Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation. Leuk Lymphoma. 2002;12:2421\u20132413.","journal-title":"Leuk Lymphoma"},{"key":"1270_CR9","doi-asserted-by":"publisher","first-page":"801082","DOI":"10.1155\/2015\/801082","volume":"2015","author":"B Malhotra","year":"2015","unstructured":"Malhotra B, Rahal AK, Farhoud H, Moore Jr DF, Kallail KJ. Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant. Case Rep Transplant. 2015;2015:801082. https:\/\/doi.org\/10.1155\/2015\/801082.","journal-title":"Case Rep Transplant."},{"key":"1270_CR10","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/01.tp.0000295987.12996.19","volume":"12","author":"R Trappe","year":"2007","unstructured":"Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation. 2007;12:1708\u201312.","journal-title":"Transplantation"},{"key":"1270_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1046\/j.1365-2141.2003.04705.x","volume":"5","author":"SH Oertel","year":"2003","unstructured":"Oertel SH, Papp-V\u00e1ry M, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol. 2003;5:830\u20135.","journal-title":"Br J Haematol"},{"key":"1270_CR12","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/jco.2009.27.15_suppl.8509","volume":"27","author":"C Gisselbrecht","year":"2009","unstructured":"Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol. 2009;27:8509-8509. https:\/\/doi.org\/10.1200\/jco.2009.27.15_suppl.8509.","journal-title":"J Clin Oncol."},{"key":"1270_CR13","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"31","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;31:3490\u20136.","journal-title":"J Clin Oncol"},{"key":"1270_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.08070715","volume":"7","author":"S Latcha","year":"2016","unstructured":"Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;7:1173\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1270_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","volume":"317","author":"JM Bland","year":"1998","unstructured":"Bland JM, Altman DG. Statistics Notes: survival probabilities (the Kaplan-Meier method). BMJ. 1998;317:1572\u201380.","journal-title":"BMJ"},{"key":"1270_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"10","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transpl. 2006;10:1065\u201372.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1270_CR17","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"25","author":"F D\u2019Amore","year":"2012","unstructured":"D\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;25:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"1270_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bmt.2015.286","volume":"51","author":"SP Robinson","year":"2016","unstructured":"Robinson SP, Boumendil A, Finel H, Blaise D, Poir\u00e9 X, Nicolas-Virelizier E, et al. Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transpl. 2016;51:365\u201371.","journal-title":"Bone Marrow Transpl"},{"key":"1270_CR19","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41409-018-0196-3","volume":"12","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Dreger P, Sureda A, Hermine O, et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. Bone Marrow Transpl. 2018;12:1553\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1270_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3324\/haematol.11360","volume":"11","author":"E Gonz\u00e1lez-Barca","year":"2007","unstructured":"Gonz\u00e1lez-Barca E, Domingo-Domenech E, Capote FJ, G\u00f3mez-Codina J, Salar A, Bauen A, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007;11:1489\u201394.","journal-title":"Haematologica"},{"key":"1270_CR21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","volume":"10","author":"S Caillard","year":"2013","unstructured":"Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: Report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;10:1302\u20139.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01270-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01270-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01270-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:25:05Z","timestamp":1630538705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01270-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01270-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr HZ reports institutional grants from Atara and Roche and travel support from Atara, Celgene, and Jansen, outside the submitted work. Dr RUT reports institutional grants from Atara and Roche and non-financial support from Roche, Atara, Celgene, Janssen and AbbVie, all outside the submitted work. All other authors have declared no relevant competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}